A detailed history of Affinity Asset Advisors, LLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 300,000 shares of BBIO stock, worth $7.12 Million. This represents 1.32% of its overall portfolio holdings.

Number of Shares
300,000
Previous 100,000 200.0%
Holding current value
$7.12 Million
Previous $2.53 Million 201.54%
% of portfolio
1.32%
Previous 0.34%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$23.91 - $31.3 $4.78 Million - $6.26 Million
200,000 Added 200.0%
300,000 $7.64 Million
Q2 2024

Aug 14, 2024

BUY
$23.0 - $31.04 $1.15 Million - $1.55 Million
50,000 Added 100.0%
100,000 $2.53 Million
Q1 2024

May 14, 2024

SELL
$27.35 - $40.45 $820,500 - $1.21 Million
-30,000 Reduced 37.5%
50,000 $1.55 Million
Q4 2023

Feb 13, 2024

BUY
$24.02 - $43.89 $1.2 Million - $2.19 Million
50,000 Added 166.67%
80,000 $3.23 Million
Q3 2023

Nov 14, 2023

SELL
$16.89 - $35.01 $86,696 - $179,706
-5,133 Reduced 14.61%
30,000 $791,000
Q2 2023

Aug 14, 2023

SELL
$13.29 - $18.01 $3.79 Million - $5.13 Million
-284,867 Reduced 89.02%
35,133 $604,000
Q1 2023

May 15, 2023

BUY
$7.17 - $18.55 $2.29 Million - $5.94 Million
320,000 New
320,000 $5.31 Million
Q1 2022

May 13, 2022

SELL
$7.34 - $17.16 $3.63 Million - $8.48 Million
-494,046 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$11.38 - $53.41 $1.83 Million - $8.57 Million
-160,389 Reduced 24.51%
494,046 $8.24 Million
Q3 2021

Nov 12, 2021

BUY
$46.87 - $64.24 $4.89 Million - $6.71 Million
104,435 Added 18.99%
654,435 $30.7 Million
Q2 2021

Aug 13, 2021

SELL
$46.47 - $63.93 $1.28 Million - $1.76 Million
-27,500 Reduced 4.76%
550,000 $33.5 Million
Q1 2021

May 14, 2021

BUY
$55.47 - $72.35 $23.4 Million - $30.6 Million
422,500 Added 272.58%
577,500 $35.6 Million
Q4 2020

Feb 12, 2021

BUY
$38.38 - $71.11 $5.95 Million - $11 Million
155,000 New
155,000 $11 Million

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $3.52B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.